A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
A Phase III Trial of Telitacicept in Patients With Ocular Myasthenia Gravis
RemeGen Co., Ltd.
120 participants
Jan 13, 2026
INTERVENTIONAL
Conditions
Summary
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America \[MGFA\] Clinical Classification Type I) will be randomized in a 1:1 ratio to receive either Telitacicept or a matching placebo. Subjects must be on a stable standard-of-care therapy and have an MG Impairment Index (PRO) ocular score of ≥6 at screening and baseline.The study consists of a screening period of up to 6 weeks and a 24-week double-blind treatment period. The dose is age and weight based via via subcutaneous injection at fixed, periodic intervals.The primary objective is to evaluate the efficacy of Telitacicept compared to placebo in treating OMG.The primary efficacy endpoint is the change from baseline in the MGII (PRO) ocular score at Week 24. Secondary endpoints include changes from baseline in other ocular and total scores from MGII, Myasthenia Gravis-Activities of Daily Living (MG-ADL), MG Clinical Absolute Score, and the 15-item Myasthenia Gravis Quality of Life Revised scale (MG-QOL15r). Safety and tolerability will be monitored throughout the study.
Eligibility
Inclusion Criteria6
- Voluntarily signed the informed consent form.
- Age 12 to 80 years, inclusive, male or female.
- Body weight ≥30 kg.
- Diagnosis of Myasthenia Gravis (MG) with documented clinical features consistent with the disease.
- Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Type I.
- On a stable standard-of-care (SOC) treatment regimen.
Exclusion Criteria12
- Concomitant autoimmune diseases requiring systemic corticosteroid therapy.
- Clinically significant laboratory abnormalities.
- Use of other immunosuppressants (not part of the stable SOC) within 1 month prior to randomization.
- Presence of an acute or chronic infection requiring treatment.
- Current active hepatitis or history of severe liver disease.
- Positive for HIV antibodies.
- Positive for syphilis antibodies (non-specific or specific).
- Poorly controlled diabetes mellitus, defined as HbA1c \>9.0% or fasting blood glucose ≥11.1 mmol/L.
- Subjects with thymoma (classified as ≤ Stage II for benign and ≥ Stage III for malignant according to the Masaoka staging system) .
- Presence of uncontrolled chronic degenerative diseases, psychiatric disorders, or neurological diseases other than MG that could interfere with study assessments.
- Other diseases causing ptosis, peripheral muscle weakness, or diplopia (e.g., Graves' ophthalmopathy, blepharospasm, progressive external ophthalmoplegia, muscular dystrophy, brainstem or cranial nerve lesions, etc.).
- Known allergy to human-derived biological products.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The dosage is administered based on the subject's age and baseline body weight, via 24weeks subcutaneous injection at fixed, periodic intervals.
The placebo contains no active ingredients. To maintain the blind, the placebo matches the active drug in all physical aspects. The double-blind treatment period will last for 24 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07249632